Mizuho Reiterates Buy on Atara Biotherapeutics, Maintains $31 Price Target
Mizuho analyst Salim Syed reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $31 price target.
Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Atara Biotherapeutics Presents New MRI And Updated Open-Label Extension Data From Phase 1 Study Of ATA188 In Progressive Multiple Sclerosis At ECTRIMS 2022 October 26-28
Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up
Patients Treated with ATA188 that Achieved CDI
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.
Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact
Atara Biotherapeutics Inc (NASDAQ:ATRA) announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel) for Epstein-Barr…
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
Gainers
Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European Journal of Heart Failure.